SEARCH

SEARCH BY CITATION

References

  • 1
    DeVita VJ, Canellos G, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975;1: 248.
  • 2
    Coltman C, Dahlberg S, Jones S. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve-year Southwest oncology group follow-up. In: SkarinA, ed., Advances in Cancer Chemotherapy. New York: Park Row, 1986.
  • 3
    Yi P, Coleman M, Saltz L, et al. Chemotherapy for large cell lymphoma: a status update. Semin Oncol 1990;17: 6073.
  • 4
    Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 10026.
  • 5
    Messori A, Vaiani M, Trippoli S, et al. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001;84: 3037.
  • 6
    Shipp M, Harrington D, Anderson J, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329: 98794.
  • 7
    Zinzani P, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients. Blood 1999;94: 338.
  • 8
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach Oncologist. 2000;5:22437.
  • 9
    Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16: 2734.
  • 10
    Maloney D, Grillo-Lopez A, White C, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90: 218895.
  • 11
    McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16: 282533.
  • 12
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92: 192732.
  • 13
    Vose J, Link B, Grossbard M, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19: 38997.
  • 14
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP  alone  in  elderly  patients  with  diffuse  large-B-cell lymphoma. N Engl J Med 2002;346: 23542.
  • 15
    Coiffier B, Herbrecht H, Tilly C. LNH 98-5 study comparing CHOP and R-CHOP in elderly patients with DLCL. 3-year median follow-up with an analysis according to co-morbidity factors. In: 2003 Meeting of the American Society of Clinical Oncology (Abstract 2395). Chicago, IL: American Society of Clinical Oncology, 2003.
  • 16
    Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18: 330217.
  • 17
    Brown M, Glick H, Harrell F, et al. Integrating economic analysis into cancer clinical trials: the National Cancer Institute—American Society of Clinical Oncology Economics Workbook. J Natl Cancer Inst Monogr 1998;24: 128.
  • 18
    Russell L, Gold M, Siegel J, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 11727.
  • 19
    Siegel J, Weinstein M, Russell L, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 133941.
  • 20
    Weinstein M, Siegel J, Gold M, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276: 12538.
  • 21
    Proctor SJ, Mackie M, Dawson A, et al. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 2002;38: 795806.
  • 22
    Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transpl 2000;6: 50612.
  • 23
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma (Comment). N Engl J Med 1995;333: 15405.
  • 24
    Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102: 198996.
  • 25
    Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96: 2399404.
  • 26
    Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 2001; 19: 40613.
  • 27
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333: 15405.
  • 28
    Doorduijn J, Buijt I, Uyl-de Groot C, et al. Quality of life (QOL) in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP (Abstract). Blood 2001;98: 1803.
  • 29
    Djulbeovic B, Hollenberg J, Woodcock T, Herzig R. Comparison of different treatment strategies for diffuse large-cell lymphomas: a decision analysis. Med Decis Making 1991;11: 18.
  • 30
    Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant 1995; 16: 46370.
  • 31
    Edelman M, Meyers F, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 1997;12: 31831.
  • 32
    ICD-10. The international statistical classification of diseases and related health problems, tenth revision. Available from: http://www.who.int/classifications/icd10/[Accessed June 10, 2004].
  • 33
    Ministère de l’Emploi et de la Solidarité. Journaux Officiels. Dans: L’Echelle Nationale de Coûts par Groupe Homogène de Malades 1999: Bulletin Officiel. 1999;99/2 bis: 3955.
  • 34
    Perrier L, Sebban C, Philip I, et al. Necessary harmonization of health cost assessment. Autologous Peripheral Blood Progenitor Cell Transplantation in France Revue D Epidemiologie Et De Sante Publique 2002;50: 393403.
  • 35
    Van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. A prospective randomised trial. Eur J Cancer 2001;37: 17819.
  • 36
    FXHistory: historical currency exchange rates. Available from: http://www.oanda.com/convert/fxhistory[Accessed June 10, 2004].
  • 37
    Kattan M, Inoue Y, Giles F, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996;125: 5418.
  • 38
    Liberato N, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997;15: 267382.
  • 39
    Messori A. Cost-effectiveness of interferon in interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol 1998;9: 38996.
  • 40
    Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 2003;6: 917.
  • 41
    Fisher RI. Treatment of aggressive non-Hodgkin’ lymphomas. Lessons from the past 10 years. Cancer 1994;74: 265761.
  • 42
    Armitage J, Cheson B. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988;6: 133547.
  • 43
    Frei E. Curative cancer chemotherapy. Cancer Res 1985;45: 652337.
  • 44
    Lee A, Connors J, Klimo P, et al. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1997;15: 174553.
  • 45
    Frenk J, Gómez-Dantés O. Globalization and the challenges to health systems. Health Affairs 2002; 21: 1605.
  • 46
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993;148: 9279.
  • 47
    Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003; 163: 163741.